Intensity Therapeutics (INTS) 10-Q 13 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Nov. 06, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-41109
Entity Registrant Name	INTENSITY THERAPEUTICS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-1488089
Entity Address, Address Line One	1 Enterprise Drive
Entity Address, Address Line Two	Suite 430
Entity Address, City or Town	Shelton
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06484-4779
City Area Code	203
Local Phone Number	221-7381
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	INTS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		13,867,697
Entity Central Index Key	0001567264
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false
Current Fiscal Year End Date	--12-31

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2024	Dec. 31, 2023	[1]
Current assets:
Cash and cash equivalents	$ 2,782,000	$ 8,556,000
Marketable debt securities	0	6,220,000
Prepaid expenses and other current assets	1,005,000	688,000
Total current assets	3,787,000	15,464,000
Right-of-use asset, net	128,000	147,000
Other assets	1,298,000	1,684,000
Total assets	5,213,000	17,295,000
Current liabilities:
Accounts payable	540,000	3,048,000
Accrued expenses	1,749,000	891,000
Lease liability, current portion	28,000	20,000
Total current liabilities	2,317,000	3,959,000
Other long-term liabilities	0	36,000
Lease liability, long-term portion	117,000	138,000
Total liabilities	2,434,000	4,133,000
Commitments and contingencies
Stockholders' equity:
Preferred stock, par value $.0001. Authorized shares of 15,000,000 as of both September 30, 2024 and December 31, 2023. None issued and outstanding as of both September 30, 2024 and December 31, 2023.	0	0
Common stock, par value $.0001. Authorized shares of 135,000,000 as of September 30, 2024 and December 31, 2023, respectively. Issued and outstanding shares of 13,863,947 and 13,709,377 as of September 30, 2024 and December 31, 2023, respectively.	1,000	1,000
Additional paid-in capital	66,380,000	63,676,000
Accumulated deficit	(63,602,000)	(50,515,000)
Total stockholders’ equity	2,779,000	13,162,000
Total liabilities and stockholders’ equity	$ 5,213,000	$ 17,295,000
[1]Derived from audited financial statements

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	135,000,000	135,000,000
Common stock, shares issued (in shares)	13,863,947	13,709,377
Common stock, shares outstanding (in shares)	13,863,947	13,709,377

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development	$ 2,151	$ 1,352	$ 8,529	$ 2,985
General and administrative	1,419	1,139	4,853	1,982
Total operating expenses	3,570	2,491	13,382	4,967
Loss from operations	(3,570)	(2,491)	(13,382)	(4,967)
Other income (expense):
Interest income	48	148	286	148
Interest expense	0	0	0	(305)
Loss on debt extinguishment	0	0	0	(2,262)
Other income (expense), net	9	14	9	20
Net loss	(3,513)	(2,329)	(13,087)	(7,366)
Preferred stock deemed dividend	0	0	0	(1,324)
Net loss attributable to common stockholders	$ (3,513)	$ (2,329)	$ (13,087)	$ (8,690)
Loss per share, basic (in dollars per share)	$ (0.25)	$ (0.17)	$ (0.95)	$ (1.26)
Loss per share, diluted (in dollars per share)	$ (0.25)	$ (0.17)	$ (0.95)	$ (1.26)
Weighted average number of shares of common stock, basic (in shares)	13,804,651	13,660,627	13,742,325	6,899,984
Weighted average number of shares of common stock, diluted (in shares)	13,804,651	13,660,627	13,742,325	6,899,984

CONDENSED STATEMENTS OF CHANGES

CONDENSED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIENCY) - USD ($) $ in Thousands	Total		Conversion Of Preferred Stock Into Common Stock	Conversion Of Convertible Notes To Common Stock	Warrants outstanding	Preferred Stock Series B Convertible Preferred	Preferred Stock Series C Convertible Preferred	Common Stock	Common Stock Conversion Of Preferred Stock Into Common Stock	Common Stock Conversion Of Convertible Notes To Common Stock	Additional Paid in Capital	Additional Paid in Capital Conversion Of Preferred Stock Into Common Stock	Additional Paid in Capital Conversion Of Convertible Notes To Common Stock	Additional Paid in Capital Warrants outstanding	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022	5,000,000
Beginning balance at Dec. 31, 2022	$ 10,000
Ending balance (in shares) at Mar. 31, 2023	5,000,000
Ending balance at Mar. 31, 2023	$ 10,000
Beginning balance (in shares) at Dec. 31, 2022						1,449,113	1,800,606	3,410,103
Beginning balance, equity at Dec. 31, 2022	(15,098)					$ 0	$ 0	$ 0			$ 23,555				$ (38,653)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	312										312
Warrants issued	159										159
Net loss	(1,336)														(1,336)
Ending balance (in shares) at Mar. 31, 2023						1,449,113	1,800,606	3,410,103
Ending balance, equity at Mar. 31, 2023	$ (15,963)					$ 0	$ 0	$ 0			24,026				(39,989)
Beginning balance (in shares) at Dec. 31, 2022	5,000,000
Beginning balance at Dec. 31, 2022	$ 10,000
Ending balance (in shares) at Sep. 30, 2023	0
Ending balance at Sep. 30, 2023	$ 0
Beginning balance (in shares) at Dec. 31, 2022						1,449,113	1,800,606	3,410,103
Beginning balance, equity at Dec. 31, 2022	(15,098)					$ 0	$ 0	$ 0			23,555				(38,653)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(7,366)
Ending balance (in shares) at Sep. 30, 2023						0	0	13,709,377
Ending balance, equity at Sep. 30, 2023	$ 15,911					$ 0	$ 0	$ 1			63,253				(47,343)
Beginning balance (in shares) at Mar. 31, 2023	5,000,000
Beginning balance at Mar. 31, 2023	$ 10,000
Series A Redeemable Convertible Preferred Stock
Conversion of preferred stock into common stock (in shares)	(5,000,000)
Conversion of preferred stock into common stock	$ (10,000)
Ending balance (in shares) at Jun. 30, 2023	0
Ending balance at Jun. 30, 2023	$ 0
Beginning balance (in shares) at Mar. 31, 2023						1,449,113	1,800,606	3,410,103
Beginning balance, equity at Mar. 31, 2023	(15,963)					$ 0	$ 0	$ 0			24,026				(39,989)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	312										312
Issuance of common stock in ATM/ public offering for cash, net issuance costs (in shares)								3,900,000
Issuance of common stock in ATM/ public offering for cash, net issuance costs	16,468										16,468
Warrants issued					$ 1,017									$ 1,017
Issuance of preferred stock for anti-dilution clauses (in shares)						100,189	164,518
Conversion of preferred stock into common stock and convertible notes into common stock (in shares)						(1,549,302)	(1,965,124)		4,124,851	1,399,716
Conversion of preferred stock into common stock and convertible notes into common stock			$ 10,000	$ 7,000					$ 1			$ 9,999	$ 7,000
Deemed dividend (in shares)								264,707
Deemed dividend	0										1,324				(1,324)
Net loss	(3,701)														(3,701)
Ending balance (in shares) at Jun. 30, 2023						0	0	13,099,377
Ending balance, equity at Jun. 30, 2023	$ 15,133					$ 0	$ 0	$ 1			60,146				(45,014)
Ending balance (in shares) at Sep. 30, 2023	0
Ending balance at Sep. 30, 2023	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of warrants and options (in shares)								12,500
Exercise of warrants and options	25										25
Stock-based compensation expense	351										351
Issuance of common stock in ATM/ public offering for cash, net issuance costs (in shares)								585,000
Issuance of common stock in ATM/ public offering for cash, net issuance costs	2,553										2,553
Warrants issued					$ 153									$ 153
Net loss	(2,329)														(2,329)
Ending balance (in shares) at Sep. 30, 2023						0	0	13,709,377
Ending balance, equity at Sep. 30, 2023	$ 15,911					$ 0	$ 0	$ 1			63,253				(47,343)
Beginning balance (in shares) at Dec. 31, 2023	0
Beginning balance at Dec. 31, 2023	$ 0
Ending balance (in shares) at Mar. 31, 2024	0
Ending balance at Mar. 31, 2024	$ 0
Beginning balance (in shares) at Dec. 31, 2023						0	0	13,709,377
Beginning balance, equity at Dec. 31, 2023	13,162	[1]				$ 0	$ 0	$ 1			63,676				(50,515)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of warrants and options (in shares)								2,500
Exercise of warrants and options	8										8
Stock-based compensation expense	1,155										1,155
Net loss	(4,603)										0				(4,603)
Ending balance (in shares) at Mar. 31, 2024						0	0	13,711,877
Ending balance, equity at Mar. 31, 2024	$ 9,722					$ 0	$ 0	$ 1			64,839				(55,118)
Beginning balance (in shares) at Dec. 31, 2023	0
Beginning balance at Dec. 31, 2023	$ 0
Ending balance (in shares) at Sep. 30, 2024	0
Ending balance at Sep. 30, 2024	$ 0
Beginning balance (in shares) at Dec. 31, 2023						0	0	13,709,377
Beginning balance, equity at Dec. 31, 2023	13,162	[1]				$ 0	$ 0	$ 1			63,676				(50,515)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(13,087)
Ending balance (in shares) at Sep. 30, 2024						0	0	13,863,947
Ending balance, equity at Sep. 30, 2024	$ 2,779					$ 0	$ 0	$ 1			66,380				(63,602)
Beginning balance (in shares) at Mar. 31, 2024	0
Beginning balance at Mar. 31, 2024	$ 0
Ending balance (in shares) at Jun. 30, 2024	0
Ending balance at Jun. 30, 2024	$ 0
Beginning balance (in shares) at Mar. 31, 2024						0	0	13,711,877
Beginning balance, equity at Mar. 31, 2024	9,722					$ 0	$ 0	$ 1			64,839				(55,118)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of warrants and options (in shares)								1,000
Exercise of warrants and options	3										3
Stock-based compensation expense	591										591
Net loss	(4,971)														(4,971)
Ending balance (in shares) at Jun. 30, 2024						0	0	13,712,877
Ending balance, equity at Jun. 30, 2024	$ 5,345					$ 0	$ 0	$ 1			65,433				(60,089)
Ending balance (in shares) at Sep. 30, 2024	0
Ending balance at Sep. 30, 2024	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of warrants and options (in shares)								87,500
Exercise of warrants and options	263										263
Stock-based compensation expense	483										483
Issuance of common stock in exchange for services (in shares)								11,750
Issuance of common stock in exchange for services	51										51
Issuance of common stock in ATM/ public offering for cash, net issuance costs (in shares)								51,820
Issuance of common stock in ATM/ public offering for cash, net issuance costs	150										150
Net loss	(3,513)														(3,513)
Ending balance (in shares) at Sep. 30, 2024						0	0	13,863,947
Ending balance, equity at Sep. 30, 2024	$ 2,779					$ 0	$ 0	$ 1			$ 66,380				$ (63,602)
[1]Derived from audited financial statements

CONDENSED STATEMENTS OF CHANG_2

CONDENSED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIENCY) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2023
At The Market Offering Agreement
Issuance costs	$ 82
IPO
Issuance costs		$ 372	$ 3,031

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (13,087)	$ (7,366)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of discount on convertible notes	0	159
Change in carrying value of right-of-use asset	19	141
Stock-based compensation expense	2,229	975
Stock issued in exchange for services	25	0
Loss on debt extinguishment	0	2,262
Changes in operating assets and liabilities, net:
Accrued interest on marketable debt securities	(134)	(111)
Prepaid expenses, other current assets, and other assets	96	(709)
Accounts payable, accrued expenses and other liabilities	(1,700)	(1,610)
Net cash used in operating activities	(12,552)	(6,259)
Cash flows from investing activities:
Purchase of marketable debt securities	(3,056)	(8,844)
Redemption of marketable debt securities	9,410	0
Net cash provided by (used in) investing activities	6,354	(8,844)
Cash flows from financing activities:
Proceeds from issuance of convertible note	0	243
Proceeds from ATM offering	232	0
Issuance costs related to ATM offering	(82)	0
Proceeds from Initial Public Offering and overallotment	0	22,425
Issuance costs related to Initial Public Offering and overallotment	0	(2,233)
Proceeds from exercise of warrants and options	274	50
Net cash provided by financing activities	424	20,485
Net (decrease) increase in cash and cash equivalents	(5,774)	5,382
Cash and cash equivalents at beginning of period	2,782	6,694
Cash and cash equivalents at end of period	8,556	1,312
Supplemental disclosure of non-cash financing activities:
Common stock issued	51	4,737
Right-of-use lease asset and operating lease liability	0	155
Warrants issued in relation to issuance of convertible notes	0	159
Warrants issued to underwriter in connection with stock issuance	0	1,170
Preferred stock deemed dividend	$ 0	$ 1,324

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Intensity Therapeutics, Inc. (the “Company”) is a biotechnology company whose treatment approach addresses both the regional and systemic nature of a patient’s cancer. The Company’s DfuseRx SM technology platform has identified a lead drug, INT230-6. The Company is based in Connecticut and was incorporated in Delaware in December 2012.

Liquidity and Plan of Operation

Liquidity and Plan of Operation	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Plan of Operation	Liquidity and Plan of Operation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“GAAP”), which contemplate continuation of the Company as a going concern. The Company is a research and development company and has not generated any revenue from its product candidates. The Company has experienced net losses and negative cash flows from operations each year since its inception. Through September 30, 2024, the Company has an accumulated deficit of $63.6 million. The Company’s operations have been financed primarily through the sale of equity securities and convertible notes. The Company’s net loss for the nine months ended September 30, 2024 was $13.1 million. The Company expects to incur significant expenses to complete development of its product candidates. The Company may never be able to obtain regulatory approval for the marketing of any of its product candidates in the United States or internationally and there can be no assurance that the Company will generate revenues or ever achieve profitability. The Company does not expect to receive significant product revenue in the near term. The Company, therefore, expects to continue to incur substantial losses for the foreseeable future. Cash and cash equivalents totaled $2.8 million as of September 30, 2024. Until such time the Company can generate substantial product revenue, the Company plans to finance its operations through a combination of equity offerings and convertible debt financings. The Company does not have any committed external source of funds. To the extent that the Company can raise additional capital through the sale of equity or convertible debt securities, the ownership interest of the existing Company stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of the common stockholders. If the Company is unable to raise additional funds through equity or debt financings when needed, the Company may be required to delay, limit, reduce or terminate its research and product development. Based on the cash and cash equivalents as of September 30, 2024, the Company believes that it has sufficient cash into the first quarter of 2025 for its projected current operations. As a result, the Company believes there is substantial doubt about its ability to continue as a going concern.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies Basis of presentation The interim condensed financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting only of normal, recurring adjustments, necessary for a fair presentation of the financial position of the Company at September 30, 2024, and its results of operations and its cash flows for the three and nine months ended September 30, 2024 and 2023. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the years ended December 31, 2023 and 2022 and notes thereto. The accompanying financial statements have been prepared in accordance with GAAP and reflect the operations of the Company. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations of the Securities and Exchange Commission relating to interim financial statements. The December 31, 2023 balance sheet information was derived from the audited financial statements as of that date. The Company neither owns nor controls any subsidiary companies. Fair value measurement The Company reports its investments at fair value. Fair value is an estimate of the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants (i.e., the exit price at the measurement date). Fair value measurements are not adjusted for transaction costs. A fair value hierarchy provides for prioritizing inputs to valuation techniques used to measure fair value into three levels: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Inputs other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company. Level 3 Unobservable inputs. Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability. An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities and Level 3 assets and liabilities involve greater judgment than Level 1 or Level 2 assets or liabilities. As of September 30, 2024 and December 31, 2023, the Company invested zero and $6.2 million, respectively in U.S. Treasury Bills, included in marketable debt securities, which were classified as available-for-sale. U.S. Treasury Bills were valued at market prices obtained from independent vendor services, which the Company believes to be reliable. In some cases, the pricing vendor may provide prices quoted by a single broker or market maker. U.S. Treasury Bills were categorized in Level 2 of the fair value hierarchy. The Company’s financial instruments, including cash equivalents and current liabilities are carried at cost, which approximates fair value due to the short-term nature of these instruments. Stock-based compensation The Company accounts for stock-based compensation to employees and non-employees, which consists of stock option grants, through the Statements of Operations based on their fair values at the date of grant. The Company calculates the fair value of option grants utilizing the Black-Scholes pricing model. The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award. Forfeitures are recognized as they occur. The Company had been a private company and lacked company-specific historical and implied volatility information for its shares. Therefore, the Company estimated its expected share price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price. Research and development costs The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, contract research organizations (“CRO”), and contract manufacturing organizations (“CMO”) in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Research and development costs are expensed in the period in which they are incurred. External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company’s clinical manufacturing and clinical development activities. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or its estimate of the level of service that has been performed at each reporting date. The Company tracks external costs based on research and development initiative, including preclinical, individual clinical study, and manufacturing activities. Internal costs consist primarily of employee-related costs and costs related to compliance with regulatory requirements. The Company does not track internal costs by program because these costs are deployed across multiple programs and, as such, are not separately classified. The Company makes estimates of accrued expenses as of each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in its accrued research and development expenses include the costs incurred for services performed by vendors in connection with research and development activities for which the Company has not yet been invoiced. In July 2024, the Company initiated a Phase 3 open-label, randomized study for certain soft tissue sarcoma subtypes, which is expected to span several years. In connection with this study, the Company recorded an advance payment of $1.7 million in December 2023, which will be applied to future invoices during and at the end of the study. As of September 30, 2024 and December 31, 2023, the advance payment balances were $1.2 million and $1.7 million, respectively, and were recorded in Other Assets in the Balance Sheet. Basic and dilutive loss per share Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Dilutive net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and stock warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per share does not include the conversion of securities that would have an anti-dilutive effect. Potential shares of common stock issuable upon the exercise of stock options and warrants are excluded from the computation of diluted weighted average shares outstanding listed in the table below because, when the Company is in a net loss position, they are anti-dilutive. There were no preferred shares or convertible notes outstanding at September 30, 2024 and 2023. As of September 30, 2024 and 2023, the following shares of common stock underlying options and warrants were excluded from the computation of diluted weighted average shares outstanding: September 30, 2024 2023 Options outstanding 1,949,629 1,081,750 Warrants outstanding 829,450 689,200 2,779,079 1,770,950 Recently issued pronouncements The Company does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material impact on its financial statements.

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2024
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consisted of the following (in thousands): September 30, December 31, Savings and checking accounts at major U.S. financial institutions $ 322 $ 367 U.S. Treasury securities money market fund 2,460 8,189 Total $ 2,782 $ 8,556

Marketable Debt Securities

Marketable Debt Securities	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Marketable Debt Securities	Marketable Debt Securities Marketable debt securities as of December 31, 2023 consisted entirely of U.S. Treasury Bills purchased with maturities over three months but less than twelve months. All marketable debt securities matured during 2024.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2024
Other Income and Expenses [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses consisted of the following (in thousands): September 30, December 31, Prepaid insurance $ 566 $ 647 Prepaid research and development costs 311 — Prepaid other 128 41 Total $ 1,005 $ 688

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses consisted of the following (in thousands): September 30, December 31, Accrued research and development costs $ 1,073 $ 439 Accrued employee compensation-related expenses 616 392 Accrued other 60 60 Total $ 1,749 $ 891

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Stockholders’ Equity	Stockholders’ Equity Initial public offering On July 5, 2023, as described in Note 1, the Company completed its IPO, issuing 3,900,000 shares of common stock at the IPO price of $5.00 per share. On July 7, 2023, the Company sold the full over-allotment of the IPO shares and issued 585,000 shares of common stock at the IPO price of $5.00 per share. At The Market Offering Agreement On July 3, 2024, the Company entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may sell and issue, from time to time, up to $15.0 million of shares of its common stock (the “Shares”) through Wainwright as the Company’s sales agent (the “ATM Offering”). The Company has no obligation to sell any of the Shares and may at any time suspend offers under the Sales Agreement or terminate the Sales Agreement pursuant to its terms. For the three and nine months ended September 30, 2024, the Company issued 51,820 shares of common stock under the ATM Agreement for net proceeds of $0.2 million.

Stock Based Compensation

Stock Based Compensation	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock Based Compensation	Stock Based Compensation The Company has a 2013 Stock Option Plan (the “2013 Plan”), which is administered by the Compensation Committee of the Company’s board of directors. Under the 2013 Plan, stock options to purchase shares of common stock could be granted to eligible employees, officers, directors and consultants of the Company. In 2021, the Company established the 2021 Stock Incentive Plan (the “2021 Plan”), authorizing the granting of equity awards for the issuance of up to 3,000,000 shares of common stock. Upon adoption of the 2021 Plan, no more shares would be issued under the 2013 Plan. Starting on January 1, 2022, the shares authorized under the 2021 Plan shall have an annual increase of the lessor of (a) 3.5% of the aggregate number of shares of common stock outstanding on the final day of the preceding calendar year, or (b) such smaller amount as determined by the Board. On January 1, 2024, an additional 479,828 shares were authorized under the 2021 Plan. As of September 30, 2024, 2,519,149 shares were available for issuance under the 2021 Plan. The Company recorded total stock-based compensation for its outstanding stock options and warrants in its Statements of Operations as follows (in thousands): Three Months Ended Nine Months Ended September 30, 2024 2023 2024 2023 Research and development $ 187 $ 186 $ 970 $ 651 General and administrative 296 165 1,259 324 Total stock-based compensation expense $ 483 $ 351 $ 2,229 $ 975 Stock options The following table summarizes the range of assumptions used to estimate the fair value of stock options issued using the Black-Scholes-Merton option pricing model: Nine Months Ended September 30, 2024 2023 Stock price $3.76 to $5.19 $6.43 Exercise price $3.76 to $5.19 $6.43 Expected volatility 97.06% to 101.55% 99.74% Risk free interest rates 4.12% to 4.46% 3.87% Expected term (years) 5 to 7 5.75 For the nine months ended September 30, 2024 and 2023, a dividend yield of 0% was used because the Company has not historically paid and does not intend to pay a dividend on common stock in the foreseeable future. The expected stock price volatility assumption was estimated based on the historical volatilities for industry peers, as the Company had no active market for its stock prior to the IPO and limited history for issuance price of its stock. The risk-free rate assumption is determined using the yield currently available on U.S. Treasury zero coupon issues with a remaining term commensurate with the expected term of the award. The expected term of the option represents the period the options are expected to be outstanding. The following table summarizes the activity for stock options for the nine months ended September 30, 2024 : Options Weighted- Weighted Average Aggregate Outstanding at December 31, 2023 1,239,750 $ 8.00 6.4 $ 1,865 Issued 798,379 $ 5.06 Exercised (88,500) $ 3.01 Forfeited and cancelled — $ — Outstanding at September 30, 2024 1,949,629 $ 7.02 7.5 $ 81 Exercisable at September 30, 2024 1,053,525 $ 8.24 6.0 $ — All options expire 10 years from date of grant. Options outstanding begin to expire in October 2024. Options that were granted to employees and consultants have vesting periods that vary by award to recipient and range from immediate vesting to a period of up to 4 years. The weighted average grant date fair value of stock options issued was $3.98 for the nine months ended September 30, 2024. As of September 30, 2024 , total unrecognized compensation cost related to options was approximately $3.0 million and is expected to be recognized over the remaining weighted average service period of 2.5 years. Warrants The following table summarizes the range of assumptions used to estimate the fair value of warrants issued using the Black-Scholes-Merton option pricing model: Nine Months Ended September 30, 2024 2023 Stock price $4.50 to $5.19 $4.50 to $5.00 Exercise price $4.50 to $5.19 $6.00 to $6.25 Expected volatility 97.06% to 100.64% 101.46% to 103.85% Risk free interest rates 4.12% to 4.39% 3.59% to 3.97% Expected term (years) 5 to 6.25 3 to 5 For the nine months ended September 30, 2024 and 2023, a dividend yield of 0% was used because the Company has not historically paid and does not intend to pay a dividend on common stock in the foreseeable future. The expected stock price volatility assumption was estimated based on the historical volatilities for industry peers, as the Company had no active market for its stock prior to the IPO and limited history for issuance price of its stock. The risk-free rate assumption is determined using the yield currently available on U.S. Treasury zero coupon issues with a remaining term commensurate with the expected term of the award. The expected term of the warrant represents the period the warrants are expected to be outstanding. The following table summarizes the activity for warrants for the nine months ended September 30, 2024 : Warrants Weighted- Weighted Average Aggregate Outstanding at December 31, 2023 801,950 $ 6.30 3.9 $ 2,096 Issued 50,000 $ 4.85 Exercised (2,500) $ 3.00 Forfeited and cancelled (20,000) $ 3.00 Outstanding at September 30, 2024 829,450 $ 6.31 3.7 $ 42 Exercisable at September 30, 2024 760,200 $ 6.36 3.3 $ 42 All warrants outstanding are exercisable for purchase of common stock. As of September 30, 2024, total unrecognized compensation cost related to warrants was approximately $0.3 million and is expected to be recognized over the remaining weighted average service period of 2.9 years. Restricted Stock In September 2024, the Company issued 11,750 restricted shares of its common stock (the “Restricted Stock”) to a consultant as compensation for its services to the Company through the end October 2024 valued at $51,000. The Restricted Stock will include a restricted legend for a period of at least six months from the date of issuance, after which time such restricted legend may be removed. During the three and nine months ended September 30, 2024, the Company recognized $25,000 to general and administrative expenses and $26,000 to prepaid expenses and other current assets.

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Leases	Leases In January 2017, the Company entered into a lease for approximately 2,500 square feet of office space in Westport, Connecticut, (the “Westport Lease”), which was subsequently extended and increased to approximately 4,000 square feet. In June 2023, the Westport Lease was terminated. In July 2023, the Company signed a 5.5-year lease for approximately 2,700 square feet of office space in Shelton, Connecticut, (the “Shelton Lease”). The Company has a one-time option to cancel the Shelton Lease after 36 months if it provides written notice before the end of month 30. A payment of approximately $47,000 would be due at the end of month 36 if the Company exercises this option. This option is not reasonably certain to occur. Rent expense for the three and nine months ended September 30, 2024 was approximately $9,000 and $26,000, respectively, and for the three and nine months ended September 30, 2023 was $3,000 and $55,000, respectively. Cash paid for operating leases for the three and nine months ended September 30, 2024 was approximately $17,000 and $38,000, respectively, and for the three and nine months ended September 30, 2023 was zero and $49,000, respectively. The following table summarizes the balance sheet classification of the operating lease asset and related lease liabilities as of September 30, 2024 and December 31, 2023 (in thousands): September 30, December 31, Right-of-use asset, net $ 128 $ 147 Lease liability, current portion 28 20 Lease liability, net of current portion 117 138 $ 145 $ 158 The following variables were used to determine the right-of-use asset and the operating lease liabilities at September 30, 2023 and 2022: September 30, September 30, Weighted average remaining lease term 4.4 years 5.4 years Weighted average operating lease discount rate 6.4 % 6.4 % Future minimum lease payments under the lease agreement as of September 30, 2024 were as follows (in thousands): Year ended 2024 (remainder of year) $ 9 2025 36 2026 37 2027 39 2028 and thereafter 46 Total lease payments 167 Less: Amounts representing interest (22) Present value of lease liabilities $ 145

Other Uncertainties

Other Uncertainties	9 Months Ended
	Sep. 30, 2024
Risks and Uncertainties [Abstract]
Other Uncertainties	Other Uncertainties The Company holds one of its patents in Russia. The payment for this patent is paid until September 15, 2025. If subsequent payments to Russia are restricted, the Company may lose this patent in Russia. The Company has no other significant business activities in Belarus, Russia or the Ukraine. The Company also holds a patent in Israel which is currently involved in military action.

Related Parties

Related Parties	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Related Parties	Related Parties In October 2023, the Company issued 80,000 warrants for consulting services to be rendered by two shareholders, which will vest over the subsequent twelve months. These warrants are valued at $198,000 and will be expensed to general and administrative expense over the subsequent twelve-month period, of which $44,500 and $134,000 were expensed during the three and nine months ended September 30, 2024.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net loss	$ (3,513)	$ (4,971)	$ (4,603)	$ (2,329)	$ (3,701)	$ (1,336)	$ (13,087)	$ (7,366)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of presentation	The interim condensed financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting only of normal, recurring adjustments, necessary for a fair presentation of the financial position of the Company at September 30, 2024, and its results of operations and its cash flows for the three and nine months ended September 30, 2024 and 2023. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the years ended December 31, 2023 and 2022 and notes thereto. The accompanying financial statements have been prepared in accordance with GAAP and reflect the operations of the Company. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations of the Securities and Exchange Commission relating to interim financial statements. The December 31, 2023 balance sheet information was derived from the audited financial statements as of that date. The Company neither owns nor controls any subsidiary companies.
Fair value measurement	The Company reports its investments at fair value. Fair value is an estimate of the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants (i.e., the exit price at the measurement date). Fair value measurements are not adjusted for transaction costs. A fair value hierarchy provides for prioritizing inputs to valuation techniques used to measure fair value into three levels: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Inputs other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company. Level 3 Unobservable inputs. Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability. An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities and Level 3 assets and liabilities involve greater judgment than Level 1 or Level 2 assets or liabilities. As of September 30, 2024 and December 31, 2023, the Company invested zero and $6.2 million, respectively in U.S. Treasury Bills, included in marketable debt securities, which were classified as available-for-sale. U.S. Treasury Bills were valued at market prices obtained from independent vendor services, which the Company believes to be reliable. In some cases, the pricing vendor may provide prices quoted by a single broker or market maker. U.S. Treasury Bills were categorized in Level 2 of the fair value hierarchy. The Company’s financial instruments, including cash equivalents and current liabilities are carried at cost, which approximates fair value due to the short-term nature of these instruments.
Stock-based compensation	The Company accounts for stock-based compensation to employees and non-employees, which consists of stock option grants, through the Statements of Operations based on their fair values at the date of grant. The Company calculates the fair value of option grants utilizing the Black-Scholes pricing model. The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award. Forfeitures are recognized as they occur. The Company had been a private company and lacked company-specific historical and implied volatility information for its shares. Therefore, the Company estimated its expected share price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price.
Research and development costs	The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, contract research organizations (“CRO”), and contract manufacturing organizations (“CMO”) in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Research and development costs are expensed in the period in which they are incurred. External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company’s clinical manufacturing and clinical development activities. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or its estimate of the level of service that has been performed at each reporting date. The Company tracks external costs based on research and development initiative, including preclinical, individual clinical study, and manufacturing activities. Internal costs consist primarily of employee-related costs and costs related to compliance with regulatory requirements. The Company does not track internal costs by program because these costs are deployed across multiple programs and, as such, are not separately classified. The Company makes estimates of accrued expenses as of each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The significant estimates in its accrued research and development expenses include the costs incurred for services performed by vendors in connection with research and development activities for which the Company has not yet been invoiced. In July 2024, the Company initiated a Phase 3 open-label, randomized study for certain soft tissue sarcoma subtypes, which is expected to span several years. In connection with this study, the Company recorded an advance payment of $1.7 million in December 2023, which will be applied to future invoices during and at the end of the study. As of September 30, 2024 and December 31, 2023, the advance payment balances were $1.2 million and $1.7 million, respectively, and were recorded in Other Assets in the Balance Sheet.
Basic and dilutive loss per share	Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Dilutive net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and stock warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per share does not include the conversion of securities that would have an anti-dilutive effect. Potential shares of common stock issuable upon the exercise of stock options and warrants are excluded from the computation of diluted weighted average shares outstanding listed in the table below because, when the Company is in a net loss position, they are anti-dilutive. There were no preferred shares or convertible notes outstanding at September 30, 2024 and 2023.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	As of September 30, 2024 and 2023, the following shares of common stock underlying options and warrants were excluded from the computation of diluted weighted average shares outstanding: September 30, 2024 2023 Options outstanding 1,949,629 1,081,750 Warrants outstanding 829,450 689,200 2,779,079 1,770,950

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	9 Months Ended
	Sep. 30, 2024
Cash and Cash Equivalents [Abstract]
Schedule of Cash and Cash Equivalents	Cash and cash equivalents consisted of the following (in thousands): September 30, December 31, Savings and checking accounts at major U.S. financial institutions $ 322 $ 367 U.S. Treasury securities money market fund 2,460 8,189 Total $ 2,782 $ 8,556

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2024
Other Income and Expenses [Abstract]
Schedule of Prepaid Expenses	Prepaid expenses consisted of the following (in thousands): September 30, December 31, Prepaid insurance $ 566 $ 647 Prepaid research and development costs 311 — Prepaid other 128 41 Total $ 1,005 $ 688

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following (in thousands): September 30, December 31, Accrued research and development costs $ 1,073 $ 439 Accrued employee compensation-related expenses 616 392 Accrued other 60 60 Total $ 1,749 $ 891

Stock Based Compensation (Table

Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Total Stock-Based Compensation	The Company recorded total stock-based compensation for its outstanding stock options and warrants in its Statements of Operations as follows (in thousands): Three Months Ended Nine Months Ended September 30, 2024 2023 2024 2023 Research and development $ 187 $ 186 $ 970 $ 651 General and administrative 296 165 1,259 324 Total stock-based compensation expense $ 483 $ 351 $ 2,229 $ 975
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions	The following table summarizes the range of assumptions used to estimate the fair value of stock options issued using the Black-Scholes-Merton option pricing model: Nine Months Ended September 30, 2024 2023 Stock price $3.76 to $5.19 $6.43 Exercise price $3.76 to $5.19 $6.43 Expected volatility 97.06% to 101.55% 99.74% Risk free interest rates 4.12% to 4.46% 3.87% Expected term (years) 5 to 7 5.75
Schedule of Share-Based Payment Arrangement, Option, Activity	The following table summarizes the activity for stock options for the nine months ended September 30, 2024 : Options Weighted- Weighted Average Aggregate Outstanding at December 31, 2023 1,239,750 $ 8.00 6.4 $ 1,865 Issued 798,379 $ 5.06 Exercised (88,500) $ 3.01 Forfeited and cancelled — $ — Outstanding at September 30, 2024 1,949,629 $ 7.02 7.5 $ 81 Exercisable at September 30, 2024 1,053,525 $ 8.24 6.0 $ —
Schedule Of Share-Based Payment Award, Warrants, Valuation Assumptions	The following table summarizes the range of assumptions used to estimate the fair value of warrants issued using the Black-Scholes-Merton option pricing model: Nine Months Ended September 30, 2024 2023 Stock price $4.50 to $5.19 $4.50 to $5.00 Exercise price $4.50 to $5.19 $6.00 to $6.25 Expected volatility 97.06% to 100.64% 101.46% to 103.85% Risk free interest rates 4.12% to 4.39% 3.59% to 3.97% Expected term (years) 5 to 6.25 3 to 5
Schedule of Warrants, Activity	The following table summarizes the activity for warrants for the nine months ended September 30, 2024 : Warrants Weighted- Weighted Average Aggregate Outstanding at December 31, 2023 801,950 $ 6.30 3.9 $ 2,096 Issued 50,000 $ 4.85 Exercised (2,500) $ 3.00 Forfeited and cancelled (20,000) $ 3.00 Outstanding at September 30, 2024 829,450 $ 6.31 3.7 $ 42 Exercisable at September 30, 2024 760,200 $ 6.36 3.3 $ 42

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Schedule of Assets and Liabilities, Lessee	The following table summarizes the balance sheet classification of the operating lease asset and related lease liabilities as of September 30, 2024 and December 31, 2023 (in thousands): September 30, December 31, Right-of-use asset, net $ 128 $ 147 Lease liability, current portion 28 20 Lease liability, net of current portion 117 138 $ 145 $ 158
Schedule of Lease, Cost	The following variables were used to determine the right-of-use asset and the operating lease liabilities at September 30, 2023 and 2022: September 30, September 30, Weighted average remaining lease term 4.4 years 5.4 years Weighted average operating lease discount rate 6.4 % 6.4 %
Schedule of Future Minimum Lease Payments, Maturity	Future minimum lease payments under the lease agreement as of September 30, 2024 were as follows (in thousands): Year ended 2024 (remainder of year) $ 9 2025 36 2026 37 2027 39 2028 and thereafter 46 Total lease payments 167 Less: Amounts representing interest (22) Present value of lease liabilities $ 145

Description of Business (Detail

Description of Business (Details) - USD ($) $ / shares in Units, $ in Thousands			9 Months Ended
	Jul. 07, 2023	Jul. 05, 2023	Sep. 30, 2024	Sep. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock, gross proceeds			$ 0	$ 22,425
Issuance costs			$ 82	$ 0
IPO
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock (in dollars per share)	$ 5	$ 5
Sale of stock, shares issued (in shares)		3,900,000
Sale of stock, gross proceeds		$ 19,500
Issuance costs		2,000
Consideration received, sale of stock		$ 17,500
Over-Allotment Option
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock (in dollars per share)	$ 5
Sale of stock, shares issued (in shares)	585,000
Sale of stock, gross proceeds	$ 2,900
Issuance costs	200
Consideration received, sale of stock	$ 2,700

Liquidity and Plan of Operati_2

Liquidity and Plan of Operation (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	[1]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (63,602)						$ (63,602)		$ (50,515)
Net loss	(3,513)	$ (4,971)	$ (4,603)	$ (2,329)	$ (3,701)	$ (1,336)	(13,087)	$ (7,366)
Cash and cash equivalents	$ 2,782						$ 2,782		$ 8,556
[1]Derived from audited financial statements

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)	1 Months Ended
	Dec. 31, 2023		Sep. 30, 2024
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Marketable debt securities	$ 6,220,000	[1]	$ 0
Phase 3 Sarcoma Study
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Advanced payment	1,700,000
Prepaid research and development expense	$ 1,700,000		$ 1,200,000
[1]Derived from audited financial statements

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)	2,779,079	1,770,950
Options outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)	1,949,629	1,081,750
Warrants outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)	829,450	689,200

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
Savings and checking accounts at major U.S. financial institutions	$ 322	$ 367
U.S. Treasury securities money market fund	2,460	8,189
Total	$ 2,782	$ 8,556	[1]
[1]Derived from audited financial statements

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Other Income and Expenses [Abstract]
Prepaid insurance	$ 566	$ 647
Prepaid research and development costs	311	0
Prepaid other	128	41
Total	$ 1,005	$ 688

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued research and development costs	$ 1,073	$ 439
Accrued employee compensation-related expenses	616	392
Accrued other	60	60
Total	$ 1,749	$ 891	[1]
[1]Derived from audited financial statements

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($) $ / shares in Units, $ in Millions				3 Months Ended	9 Months Ended
	Jul. 03, 2024	Jul. 07, 2023	Jul. 05, 2023	Sep. 30, 2024	Sep. 30, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Common stock, shares issued (in shares)				13,863,947	13,863,947	13,709,377
IPO
Class of Stock [Line Items]
Sale of stock, shares issued (in shares)			3,900,000
Sale of stock (in dollars per share)		$ 5	$ 5
Consideration received, sale of stock			$ 17.5
Over-Allotment Option
Class of Stock [Line Items]
Sale of stock, shares issued (in shares)		585,000
Sale of stock (in dollars per share)		$ 5
Common stock, shares issued (in shares)		585,000
Consideration received, sale of stock		$ 2.7
At The Market Offering Agreement
Class of Stock [Line Items]
Sale of stock, shares issued (in shares)	15,000,000			51,820	51,820
Consideration received, sale of stock				$ 0.2	$ 0.2

Stock Based Compensation - Narr

Stock Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	2 Months Ended	3 Months Ended		9 Months Ended
	Jan. 01, 2024	Sep. 30, 2024	Oct. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Jan. 01, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award vesting period						4 years
Weighted average grant date fair value of stock options, issued (in dollars per share)						$ 3.98
Unrecognized compensation cost		$ 3,000		$ 3,000		$ 3,000
Issuance of common stock in exchange for services				51
Stock issued in exchange for services						25	$ 0
Total stock-based compensation expense				483	$ 351	2,229	$ 975
Share-Based Payment Arrangement, Nonemployee
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense				26		$ 26
Options outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Dividend yield percentage						0%	0%
Expiration period						10 years
Unrecognized compensation cost period						2 years 6 months
Warrants outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Dividend yield percentage						0%	0%
Unrecognized compensation cost period						2 years 10 months 24 days
Warrants, unrecognized compensation cost		$ 300		300		$ 300
Restricted Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Issuance of common stock in exchange for services (in shares)		11,750
Restricted legend period		6 months
Stock issued in exchange for services				$ 25		$ 25
Restricted Stock | Subsequent Event
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Issuance of common stock in exchange for services			$ 51
2021 Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares available for grant (in shares)									3,000,000
Number of shares available for grant (in shares)		2,519,149		2,519,149		2,519,149
Increase in amount of shares percentage								3.50%
Number of shares authorized (in shares)	479,828
2013 Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares available for grant (in shares)									0

Stock Based Compensation - Sche

Stock Based Compensation - Schedule of Stock-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	$ 483	$ 351	$ 2,229	$ 975
Research and development
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	187	186	970	651
General and administrative
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	$ 296	$ 165	$ 1,259	$ 324

Stock Based Compensation - Sc_2

Stock Based Compensation - Schedule of Fair Value Stock Issued (Details) - Options outstanding - $ / shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock price (in dollars per share)		$ 6.43
Exercise price (in dollars per share)		$ 6.43
Expected volatility		99.74%
Risk free interest rates		3.87%
Expected term (years)		5 years 9 months
Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock price (in dollars per share)	$ 3.76
Exercise price (in dollars per share)	$ 3.76
Expected volatility	97.06%
Risk free interest rates	4.12%
Expected term (years)	5 years
Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock price (in dollars per share)	$ 5.19
Exercise price (in dollars per share)	$ 5.19
Expected volatility	101.55%
Risk free interest rates	4.46%
Expected term (years)	7 years

Stock Based Compensation - Sc_3

Stock Based Compensation - Schedule of Stock Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Options
Outstanding, beginning balance (in shares)	1,239,750
Issued (in shares)	798,379
Exercised (in shares)	(88,500)
Forfeited and cancelled (in shares)	0
Outstanding, ending balance (in shares)	1,949,629	1,239,750
Exercisable, ending balance (in shares)	1,053,525
Weighted- Average Exercise Price
Outstanding, beginning balance (in dollars per share)	$ 8
Issued (in dollars per share)	5.06
Exercised (in dollars per share)	3.01
Forfeited and cancelled (in dollars per share)	0
Outstanding, ending balance (in dollars per share)	7.02	$ 8
Exercisable, ending balance (in dollars per share)	$ 8.24
Weighted Average Remaining Contractual Term (in years)
Outstanding (in years)	7 years 6 months	6 years 4 months 24 days
Exercisable (in years)	6 years
Aggregate Intrinsic Value (in thousands)
Outstanding	$ 81	$ 1,865
Exercisable	$ 0

Stock Based Compensation - Sc_4

Stock Based Compensation - Schedule of Fair Value Warrants (Details) - Warrants outstanding - $ / shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock price (in dollars per share)	$ 4.50	$ 4.50
Exercise price (in dollars per share)	$ 4.50	$ 6
Expected volatility	97.06%	101.46%
Risk free interest rates	4.12%	3.59%
Expected term (years)	5 years	3 years
Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock price (in dollars per share)	$ 5.19	$ 5
Exercise price (in dollars per share)	$ 5.19	$ 6.25
Expected volatility	100.64%	103.85%
Risk free interest rates	4.39%	3.97%
Expected term (years)	6 years 3 months	5 years

Stock Based Compensation - Sc_5

Stock Based Compensation - Schedule of Warrants Activity (Details) - Warrants outstanding - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Warrants
Outstanding, beginning balance (in shares)	801,950
Issued (in shares)	50,000
Exercised (in shares)	(2,500)
Forfeited and cancelled (in shares)	(20,000)
Outstanding, ending balance (in shares)	829,450	801,950
Exercisable (in shares)	760,200
Weighted- Average Exercise Price
Outstanding, beginning balance (in dollars per share)	$ 6.30
Issued (in dollars per share)	4.85
Exercised (in dollars per share)	3
Forfeited and cancelled (in dollars per share)	3
Outstanding, ending balance (in dollars per share)	6.31	$ 6.30
Exercisable (in dollars per share)	$ 6.36
Weighted Average Remaining Contractual Term (in years)
Outstanding	3 years 8 months 12 days	3 years 10 months 24 days
Exercisable	3 years 3 months 18 days
Aggregate Intrinsic Value (in thousands)
Outstanding	$ 42	$ 2,096
Exercisable	$ 42

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jul. 31, 2023 ft²	Feb. 28, 2017 ft²	Jan. 31, 2017 ft²
Leases [Abstract]
Area of land | ft²					2,700	4,000	2,500
Term of contract					5 years 6 months
Term of contract					36 months
Term of contract, written notice					30 months
Payments for rent			$ 47
Operating lease expense	$ 9	$ 3	26	$ 55
Operating lease payments	$ 17	$ 0	$ 38	$ 49

Leases - Balance Sheet Classifi

Leases - Balance Sheet Classification (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Leases [Abstract]
Right-of-use asset, net	$ 128	$ 147	[1]
Lease liability, current portion	28	20	[1]
Lease liability, net of current portion	117	138	[1]
Present value of lease liabilities	$ 145	$ 158
[1]Derived from audited financial statements

Leases - Lease, Cost (Details)

Leases - Lease, Cost (Details)	Sep. 30, 2024	Sep. 30, 2023
Leases [Abstract]
Weighted average remaining lease term	4 years 4 months 24 days	5 years 4 months 24 days
Weighted average operating lease discount rate	6.40%	6.40%

Leases - Maturity (Details)

Leases - Maturity (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Leases [Abstract]
2024 (remainder of year)	$ 9
2025	36
2026	37
2027	39
2028 and thereafter	46
Total lease payments	167
Less: Amounts representing interest	(22)
Present value of lease liabilities	$ 145	$ 158

Other Uncertainties (Details)

Other Uncertainties (Details)	Sep. 30, 2024 patent
Risks and Uncertainties [Abstract]
Number of patents held	1

Related Parties (Details)

Related Parties (Details) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Oct. 31, 2023 USD ($) shareholder shares
Related Party Transaction [Line Items]
Number of shareholders | shareholder					2
Vesting period					12 months
General and administrative	$ 1,419,000	$ 1,139,000	$ 4,853,000	$ 1,982,000
Related Party
Related Party Transaction [Line Items]
Warrants issued (in shares) | shares					80
Warrants, value					$ 198,000
General and administrative	44,500		134,000
Related party transaction	20,010		10,850
Accrued expenses	$ 9,160		$ 9,160